AAHRPP Releases 2010 Metrics on Human Research Protection Programs Performance
Improving the quality of human research protection programs is a top priority for AAHRPP. Effective and efficient systems of oversight within organizations provide better protections for research participants and produce higher quality research. And collectively, they raise the bar globally to ensure research participants are safe and respected.
From data supplied by client organizations in 2010, AAHRPP has compiled an information database to help research organizations, researchers, sponsors, government agencies, and participants identify and support high-performing practices for human research protection programs (HRPPs).
Published here are the 2010 metrics for HRPP performance. The data range from types of research and conformance with regulations and guidance to financial and personnel resources and IRB review times.
A PDF version of the 2010 metrics will be available shortly. The 2009 metrics are available on the Website here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
